APVO
NASDAQ
$4.76
Aptevo Therapeutics Inc (APVO)
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company is headquartered in Seattle, Washington.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $25.50 (+436.28%)
Market Cap
$5.50M
P/B Ratio
0.49
Price Chart
Valuation
Market Cap$5.50M
Forward P/E3.89
P/S2.70
P/B0.49
Profitability
Gross Profit (TTM)$345K
EBITDA-$26M
EPS-$55.82
Growth & Risk
FCF 5Y CAGR+0.80%
Sharpe Ratio-2.03